Correction to: Vildagliptin Attenuates Huntington’s Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model | Zendy

AI Assistant Blog Pricing

Correction to: Vildagliptin Attenuates Huntington’s Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.